W81XWH20C0030
Definitive Contract
Overview
Government Description
CRYOPRESERVED PLATELET (CPP) DEVELOPMENT FOR US FDA LICENSURE
Awardee
Awarding / Funding Agency
Place of Performance
Rockville, MD 20850 United States
Pricing
Cost Plus Fixed Fee
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Est. Average FTE
31
Related Opportunity
Analysis Notes
Amendment Since initial award the Potential Award value has increased 20% from $29,252,092 to $35,107,589.
Cellphire was awarded
Definitive Contract W81XWH20C0030 (W81XWH-20-C-0030)
for Cryopreserved Platelet (CPP) Development For Us Fda Licensure
worth up to $35,107,589
by Defense Health Agency
in December 2019.
The contract
has a duration of 6 years 4 months and
was awarded
through solicitation Cryopreserved Platelet (CPP) Development for U.S. Food and Drug Administration Licensure
with a Small Business Total set aside
with
NAICS 541715 and
PSC AN94
via direct negotiation acquisition procedures with 3 bids received.
As of today, the Definitive Contract has a total reported backlog of $13,006,207 and funded backlog of $2,278,531.
DOD Announcements
Dec 2019:
Cellphire Inc.,* Rockville, Maryland, was awarded a $29,252,092 cost-plus-fixed-fee contract for Cryopreserved platelet development for U.S. Food and Drug Administration licensure. Bids were solicited via the internet with three received. Work will be performed in Rockville, Maryland, with an estimated completion date of July 19, 2026. Fiscal 2019 research, development, test and evaluation funds in the amount of $2,587,158 were obligated at the time of the award. U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland, is the contracting activity (W81XWH-20-C-0030).
Mar 2024: Cellphire Inc., Rockville, Maryland, is awarded $20,000,000 for a cost-reimbursement, ceiling increase, in-scope modification (W81XWH-20-C-0030) to achieve a commercially viable cryopreserved platelet product for U.S. Food and Drug Administration licensure. The new contract ceiling is $44,909,972. Place of performance is Frederick, Maryland. The period of performance is Dec. 20, 2019, to July 31, 2028. The awardee will conduct all development, test and evaluation, manufacturing, and regulatory activities to achieve an FDA-licensed cryopreserved platelet product that is suitable for both civilian and military use. The awardee will explore development strategies that will enable rapid licensure and availability of CPP. Fiscal 2024 research, development, test, and evaluation funding is obligated at the time of award. The U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland, is the contracting activity.
Mar 2024: Cellphire Inc., Rockville, Maryland, is awarded $20,000,000 for a cost-reimbursement, ceiling increase, in-scope modification (W81XWH-20-C-0030) to achieve a commercially viable cryopreserved platelet product for U.S. Food and Drug Administration licensure. The new contract ceiling is $44,909,972. Place of performance is Frederick, Maryland. The period of performance is Dec. 20, 2019, to July 31, 2028. The awardee will conduct all development, test and evaluation, manufacturing, and regulatory activities to achieve an FDA-licensed cryopreserved platelet product that is suitable for both civilian and military use. The awardee will explore development strategies that will enable rapid licensure and availability of CPP. Fiscal 2024 research, development, test, and evaluation funding is obligated at the time of award. The U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland, is the contracting activity.
Status
(Open)
Last Modified 10/11/23
Period of Performance
12/20/19
Start Date
12/31/25
Current End Date
4/19/26
Potential End Date
Obligations and Backlog
$22.1M
Total Obligated
$24.4M
Current Award
$35.1M
Potential Award
$2.3M
Funded Backlog
$13.0M
Total Backlog
Award Hierarchy
Definitive Contract
W81XWH20C0030
Subcontracts
Activity Timeline
Opportunity Lifecycle
Procurement history for W81XWH20C0030
Transaction History
Modifications to W81XWH20C0030
People
Suggested agency contacts for W81XWH20C0030
Competition
Number of Bidders
3
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Performance Based Acquisition
Yes
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Defense Program
None
DoD Claimant Code
Services
IT Commercial Item Category
Not Applicable
Awardee UEI
F42VPQJ8LJL4
Awardee CAGE
48GV8
Agency Detail
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT0986
Created By
kelly.r.green.civ.ht9425@health.mil
Last Modified By
kelly.r.green.civ.ht9425@health.mil
Approved By
kelly.r.green.civ.ht9425@health.mil
Legislative
Legislative Mandates
None Applicable
Performance District
MD-08
Senators
Benjamin Cardin
Chris Van Hollen
Chris Van Hollen
Representative
Jamie Raskin
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research, Development, Test, and Evaluation, Army (021-2040) | Department of Defense-Military | Research and development contracts (25.5) | $13,083,317 | 73% |
| Defense Health Program, Defense (097-0130) | Department of Defense-Military | Research and development contracts (25.5) | $4,825,248 | 27% |
Modified: 10/11/23